Peutz-Jeghers Syndrome – Definition

Peutz-Jeghers syndrome (PJS, OMIM #175200) is a genetic disease caused by a heterozygous mutation in the STK11 gene. It is characterized by the association of gastrointestinal polyps, mucocutaneous pigmentation, and a predisposition to malignant diseases.

Synonym:

PJS

Gene:

STK11

Gen­e products:

STK11 (serine/threonine protein kinase)

Function:

Tumor suppressor

  • Apoptosis mediated by interaction with the p53 signaling pathway
  • Activation of TSC2 leads to the accumulation of mTOR

Pattern of inheritance:

Autosomal dominant, around 25% de novo mutations

Prevalence:

Unknown

Genotype-phenotype correlation

Not clear

Penetrance:

Clinical manifestations have not yet been found in any of the patients with a STK11 mutation.

Overview of the Chapters on This Page:

  • Clinical Presentation

  • Special Features of Treatment

  • Recommendations for Early Detection in Your Patients
  • Further Information (e.g., Links to Support Groups)

  • Clinical Presentation

  • Special Features of Treatment

  • Recommendations for Early Detection in Your Patients
  • Further Information (e.g., Links to Support Groups)

Peutz-Jeghers Syndrome – Diagnosis

Suspected Diagnosis

Peutz-Jeghers syndrome is suspected when the following findings apply:

  • ≥ 2 intestinal PJS-type polyps (hamartomatous, intestinal polyps)
  • Mucocutaneous pigment spots
  • Gynecomastia in men as the result of estrogen-producing Sertoli cell testicular tumors
  • Condition following invagination, especially in children or young adults

Genetic Diagnostics

The diagnosis of “Peutz-Jeghers syndrome” is confirmed by the detection of a heterozygous germline mutation in the STK11 gene through sequence analysis and, if necessary, a subsequent deletion/duplication analysis. Panel examinations consisting of multiple genes, as well as exome or genome sequencing, may also be helpful.

Diagnostic Criteria

The diagnosis of “Peutz-Jeghers syndrome” is considered to be confirmed when there is evidence of a heterozygous germline mutation in the STK11 gene or one of the following findings:

  • ≥ 2 histologically confirmed harmartomatous PJS-type polyps
  • Any number of PJS-type polyps in a person who has at least one close relative with PJS
  • Characteristic mucocutaneous pigmentation in a person who has at least one close relative with PJS
  • Any number of PJS-type polyps in a person with characteristic mucocutaneous pigmentation

Differential Diagnoses

Clinical Presentation

What is characteristic of Peutz-Jeghers Syndrome is the association of gastrointestinal polyps and mucocutaneous pigmentation. The risk of gastrointestinal and extraintestinal malignancies is significantly increased.

Polyps

Polyps may occur throughout the entire gastrointestinal tract but are most common in the small intestine (with the highest density in the jejunum, followed by the ileum and the duodenum). Polyps can occur outside of the gastrointestinal tract as well (renal pelvis, urinary bladder, ureters, lungs, nose, and gall bladder). Their malignant potential is currently unclear. The polyps can cause complications such as intestinal obstructions, rectal prolapse, or severe gastrointestinal hemorrhaging.

The average age when the first gastrointestinal symptoms appear is 10 years of age, with the first polypectomy on average being performed at the age of 13.

Mucocutaneous Pigmentation

It is rare for the characteristic melanocytic maculae to exist at birth already; they typically develop by age 5. The pigmentation fades during puberty and adulthood. The maculae are dark blue to dark brown in color and occur most commonly in the perioral region, on the eyes and nostrils, on the buccal mucosa, and in the perianal region. Hyperpigmented maculae on the fingers are also common. No risk of malignancy is associated with melanocytic maculae.

Gonadal Tumors

Female PJS patients have an increased risk of sex cord tumors with annular tubules (SCTAT) and mucinous tumors of the ovaries and tubes, which regularly develop bilaterally and have a benign progression.

Male PJS patients have an increased risk of large calcifying Sertoli cell tumors (LCST) of the testicles. These tumors release estrogen and generally do not exhibit any malignant transformation.

Malignancies

Manifestation Location Risk of Manifestation Age
Colorectal 39% 42 – 46 years
Stomach 29% 30-40 years
Small intestine 13% 37-42 years
Mammary 32% – 54% 37-59 years
Ovary (mostly SCTAT) 21% 28 years
Cervix (adenoma malignum) 10% 34-40 years
Uterus 9% 43 years
Pancreas 11% – 36% 41-52 years
Testicles (Sertoli cell tumor) 9% 6-9 years
Lung 7% – 17% 47 years

Special Features of Treatment

Polyps > 1 cm in size should be removed prophylactically to prevent long-term complications and reduce the risk of a malignant transformation.

Malignant diseases should be treated according to the pertinent protocols.

Diagnosis of Peutz-Jeghers Syndrome- What's Next?

Once diagnosed, it is recommended that a cancer predisposition specialist manage the patient. The following section explains whether cancer screening tests or other measures are necessary and how they should be performed. Some additional information, including links to support groups, is also included at the end of this page.

Diagnosis of Peutz-Jeghers Syndrome- What's Next?

Once diagnosed, it is recommended that a cancer predisposition specialist manage the patient. The following section explains whether cancer screening tests or other measures are necessary and how they should be performed. Some additional information, including links to support groups, is also included at the end of this page.

Recommendations for Early Detection in Your Patients

The AACR 2024 guidelines recommend specific surveillance measures

Gastrointestinal Tract

  • Esophagogastroduodenoscopy, video capsule endoscopy, or magnetic resonance enterography and colonoscopy at 8 years (or earlier if symptoms occur)
    • If there are polyps -> repeat every 3 years
    • If there are no polyps -> repeat at the age of 18
  • Families should be educated to recognize the signs and symptoms of intussusception and to promptly seek urgent care is essential when these signs and symptoms are observed
  • Healthcare providers should be able to identify the polyp lead point of an intussusception

Gonads, Mammary Glands, Ovaries, Cervix, Uterus

  • Annual physical exams should assess:
    •  Linear growth
    •  Breast tissue development
    •  Testicular volume
  • For female patients with Peutz-Jeghers syndrome (PJS) experiencing precocious puberty:
    •   A pelvic ultrasound is recommended to check for any masses
    •   Referral to an endocrinologist should be made
  • In adulthood, screening for the following malignancies should start at age 25 or older. Patients with PJS are at increased risk for:
    •   Breast cancer
    •   Gynecologic cancer
    •   Pancreatic cancer
    •   Lung cancer

Peutz-Jeghers Syndrome – Further Information

Open Clinical Trials/ Registries